'It's game over. It's mRNA or nothing:' Expert on future of vaccines
Pfizer (PFE) and its partner BioNTech (BNTX) recently got FDA full approval for the most widely-approved and sought after COVID-19 vaccine in the world, to date.
It signals an important change in how vaccines of the future could look, according to Arnaud Bernaert, formerly head of Global Health and Healthcare at the World Economic Forum.
. . .
The potential for mRNA was recognized early. "mRNA vaccines represent a promising alternative to conventional vaccine approaches because of their high potency, capacity for rapid development and potential for low-cost manufacture and safe administration," according to a 2018 article in Nature.
. . .
"If success needs to be defined as a function of the agility of a manufacturer to be able to reposition the DNA template for combating the next variant, I don't think the U.S. and Europe will do anything else but buy mRNA vaccines"
. . .
But the pandemic also arrived after early development hurdles had been overcome for the technology. That included the method of delivery, lipid nanoparticles. And within the timeframe of getting the vaccines authorized, Moderna was first to reduce the storage temperatures needed from ultra-cold to normal freezer temperatures.
. . .
Already, mRNA companies have achieved improving stability at warmer temperatures compared to ultra-cold temperatures for the first doses. For now, however, the process is "crude,"
. . .
Whatever the future holds, mRNA is set to dominate. "Viral vector technologies are going to become obsolete," Bernaert said.
more. . .